In today's news roundup, we feature a discussion with Ben Nowell, Ph.D., director of Patient Centered Research for the Global Healthy Living Foundation, which five years ago launched ArthritisPower, a mobile app used in healthcare research. Learn more in this interview.
There are many treatments and strategies to address fatigue in rheumatoid arthritis (RA) patients, but no one approach works for all patients. In this slideshow, we highlight key takeaways from a recent review that highlights key strategies for treating fatigue in RA.
New research published in Arthritis and Rheumatology shows that vitamin D and marine omega‐3 fatty acids (n‐3 FA) do not offer long-term relief from knee pain, stiffness or function in older adults with chronic knee pain.
French researchers writing in Arthritis and Rheumatology report that of 609 surveyed spondyloarthritis patients self-isolating at home due to COVID-19, most say their condition has progressed while in isolation and for some, the change has been considerable.
In this week's news roundup from Rheumatology Network, we feature a series of studies that focus on new treatments for rheumatic disease. We also highlight the newly approved secukinumab (Cosentyx, Novartis) for active non-radiographic axial spondyloarthritis (axSpA). Today, we feature a discussion with Dr. Alexis Ogdie-Beatty and Kelly Gavigan, the lead researcher on a recent study about the overlap between axSpA and fibromyalgia.
A steering committee of the American Society for Bone Mineral Research recently issued COVID-19 treatment guidelines for patients receiving osteoporosis treatments. In this interview, E. Michael Lewiecki, M.D., director of the New Mexico Clinical Research and Osteoporosis Center and a University of New Mexico program called Bone Health TeleECHO, shares his best practices for treating osteoporosis patients during the pandemic.
Secukinumab, an IL-17a inhibitor currently approved in the United States for moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis, has been approved by the U.S. Food and Drug Administration for the treatment of active non-radiographic axial spondyloarthritis.